Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells.

PMID 21139058 ↗2010Reported benefit

Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells.

RatOtherSprague-DawleyMaleOral (daily) and intravenous (single)During angioplasty and daily thereafter

Model: Balloon angioplasty of the carotid artery (vascular injury/restenosis)

F 16618 dose-dependently reduced carotid restenosis after angioplasty by inhibiting TNF-alpha, MMP7 and smooth muscle cell migration and proliferation.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells.

Evidence by therapy association

Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells.